ATF4 and glioma: We previously reported that IDHmt enhances the ERS sensitivity of glioma cells by activating the PERK/ATF4 axis, suggesting that the PERK arm of UPR signaling could be a potential target for glioma therapy.[32] Building on this, we sought to determine whether activated PERK could further trigger the M1‐like polarization of GAMs through promoting cholesterol excretion from glioma cells.